Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)

NCT02996890 PHASE1 COMPLETED

Double blinded, randomized, placebo-controlled, dose finding, multi-center, phase 1 trial in 48 healthy volunteer subjects. After completion of screening procedures, the subjects are randomized to one of four treatment groups (different dosage strengths and placebo) All subjects will receive study treatment at day 0 and will return on day 28. Subjects randomized to treatment groups with two vaccinations will receive a second treatment at day 28. Subjects will return on day 56 for the final visit.

Details

Lead sponsor	Themis Bioscience GmbH
Phase	PHASE1
Status	COMPLETED
Enrolment	48
Start date	Wed May 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Zika Virus

Interventions

• MV-ZIKA
• Placebo

Countries

Austria